牛股频现！海马汽车6天5板！海陆重工5连板！

Group 1: Market Overview - A-shares opened lower on November 7, with all three major indices declining [2] - In the market, sectors such as Hainan Free Trade and chemicals showed strength, while storage chips, CPO concepts, and electrical equipment faced significant declines [3] Group 2: Hainan Free Trade Zone - Hainan Free Trade concept stocks were active, with Haima Automobile achieving five consecutive trading limits [4] - The official launch of the Hainan Free Trade Port's full island closure operation is set for December 18, 2023, alongside the implementation of new duty-free shopping policies, leading to increased shopping amounts, items, and visitors compared to previous years [6] Group 3: Nuclear Energy Sector - The nuclear power concept showed strength, particularly in thorium molten salt technology, with companies like Hailu Heavy Industry and Lansi Heavy Industry experiencing significant stock gains [6] - The 2025 China Nuclear Energy High-Quality Development Conference will be held in Shenzhen, focusing on cutting-edge nuclear technology and industry chain collaboration [8] Group 4: Electric Vehicle Sector - Xpeng Motors saw a nearly 5% increase in stock price, driven by the pre-sale of the X9 Super Range model, which has set a record for pre-sale orders [10][12] - The X9 model has two versions, with starting prices of 350,000 yuan and 370,000 yuan respectively [10] Group 5: Semiconductor Sector - Semiconductor stocks, including Huahong Semiconductor, experienced declines, with Huahong's stock dropping over 3% after announcing a record high revenue of $635.2 million for Q3 2025, a 20.7% year-on-year increase [12] - The company's gross margin was reported at 13.5%, with a significant drop in net profit attributable to shareholders [12] Group 6: Biotechnology Sector - BeiGene's stock rose over 3% following the announcement of Q3 revenue surpassing 10 billion yuan, marking a 41.1% year-on-year growth [12] - The growth was attributed to the strong sales of BTK inhibitor Bruton’s Tyrosine Kinase and PD-1 inhibitor Tislelizumab, along with sales growth from Amgen's licensed products [13]